RGS has been ticking boxes all year.
Monday's announcement was the big one. It looks like the company has a unique (via it secretions technology) and efficacious product, that has good shot at becoming a becoming a commercial proposition in a key growth market.
It was good to see RGS expanding a bit more about Progenze in today's announcement.
What would be good to hear as well would be about Progenza's potential for other medical conditions, with projected timelines/licensing strategies etc.
RGS Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
